UroGen Posts $89M in Q3 Revenue, Extending Zusduri Ramp
URGN has more than doubled off its 52-week low of $16.5.
Summary
UroGen reported third-quarter revenue of $89M, a sharp step up from the growth pace it showed earlier this year, though the quarter missed expectations as JELMYTO declined. That follows Q2 2026, when revenue rose 199% on Zusduri sales and the net loss narrowed, so the top line is still climbing off that base. Zusduri generated $68.0M in revenue in the third quarter, and the company cut its 2026 JELMYTO revenue guidance to approximately $90M. The quarter's net loss narrowed to $1.5 million ($0.03 per share) from $33.3 million a year earlier, and the company held cash and marketable securities of $90.5 million at September 30, 2026. The number lands against a market cap near $1.7B, meaning the quarterly top line is now a large fraction of the company's entire valuation — the sales ramp is the whole thesis. It also comes after the FDA accepted the NDA for UGN-103, the next-generation mitomycin formulation, on October 19, giving the launch story a second leg if approved.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — UroGen's Q3 net loss narrowed to $1.5 million ($0.03 per share) from $33.3 million a year earlier, with cash and marketable securities of $90.5 million at September 30, 2026.
At the time of this announcement, URGN was trading at $34.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $16.50 to $50.81. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.